A cohort study in patients with StageIIIB/IVnon-small cell lung cancer, who had treated as 1st-line Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab, and 2nd-line by Erlotinib
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000006079
- Lead Sponsor
- Yamagata University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
1)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method